Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2021-09-29 Earnings Release
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Interim Results for the 6months ended 30 June 2021
Earnings Release Classification · 1% confidence The document explicitly states 'INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021'. This clearly indicates a comprehensive financial report covering a period shorter than a full year (six months). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it also mentions Board changes, the primary focus and structure are that of a financial results announcement for a half-year period. The document is substantial (47,641 chars), confirming it is the report itself, not just an announcement of the report (RPA). H1 2021
2021-09-29 English
IMM RNS Interims Results 29 September 2021 FINAL VERSION.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021' and contains detailed financial statements, including cash balances, loss for the period, R&D expenses, and loss per share. It also includes a Chairman's Statement and a detailed Financial Review. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2021
2021-09-29 English
Corporate Update
Management Reports Classification · 1% confidence The document is identified by the RNS Number (2842N) and the header 'RNS | 29 SEPTEMBER 2021'. It is titled 'CORPORATE UDPATE' and discusses significant internal changes, including corporate reorganization, delisting intention from Euronext, cost savings, and updates on the product development portfolio (Lupuzor™, BioAMB, BioCin). It explicitly mentions that 'ImmuPharma today, through a separate announcement, also released its Interim results for the six months ended 30 June 2021.' This structure—a general corporate update released via RNS, referencing a separate, more detailed financial report (Interim results)—suggests this document itself is a general regulatory announcement rather than the comprehensive Interim Report (IR) or Annual Report (10-K). Since it is a formal announcement disseminated through the RNS system that doesn't fit perfectly into the other specific categories (like DIRS, DIV, ER, etc.), the most appropriate classification is the general regulatory filing category.
2021-09-29 English
Corporate Update
Regulatory Filings Classification · 1% confidence The document is explicitly labeled with "RNS | 29 SEPTEMBER 2021" and contains the heading "CORPORATE UDPATE". It details significant internal changes, including corporate reorganization (merging subsidiaries, de-listing from Euronext), strategic focus shifts in product development, and cost savings projections. Crucially, it mentions that "ImmuPharma today, through a separate announcement, also released its Interim results for the six months ended 30 June 2021." This structure—a broad update on corporate activities, strategy, and management changes, released via RNS, and referencing other simultaneous filings (like Interim Results)—is characteristic of a general regulatory announcement rather than a specific, comprehensive report like a 10-K or IR. Since it is a formal announcement disseminated through the Regulatory News Service (RNS) detailing various corporate actions, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general category for such market updates that don't fit the more specific categories like ER, DIV, or DIRS.
2021-09-29 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 6654M'. It announces a 'Second Price Monitoring Extension' for a security, which is a specific, time-sensitive operational announcement related to trading on the London Stock Exchange. This type of general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory News Service). It is not a report itself, but a notification.
2021-09-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1916 characters) and begins with 'RNS Number : 6646M'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, which is approved as a Primary Information Provider. This is a general regulatory announcement that does not fit the specific categories like ER, IR, 10-K, or DIV. Therefore, it falls under the general Regulatory Filings category.
2021-09-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.